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Brain insulin signaling in Alzheimer’s disease 
 
 
Abstract 
 
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder and the most 
common cause of dementia affecting elderly people. Its pathological hallmarks are the 
presence of extracellular aggregates of amyloid-β peptide (Aβ), also known as senile 
plaques, and intracellular clusters of hyperphosphorylated tau protein, commonly  
called neurofibrillary tangles (NFTs). Classically, the brain was considered to be 
insulin-insensitive, but evidence has proved the contrary and now it is widely accepted 
that insulin and IGF-1 have neuromodulatory actions. Insulin signaling is involved in 
various neuronal functions such as synapse transmission, cognition, learning and 
memory. Insulin resistance, together with AβOs neurotoxicity, neuronal metabolic 
stress and neuroinflammation, has been shown to play a role in AD pathogenesis. In 
this review we will describe the connection between neuronal insulin signaling and the 
pathogenesis and progression of AD, as well as the new promising therapeutic 
approaches focused on the insulin signaling pathway that are being researched, such 
as intranasal insulin or insulin sensitizing agents. 
 
Keywords: Alzheimer’s disease, brain insulin signaling, amyloid-β oligomers, tau 
hyperphosporylation, neuroinflammation, TNF-α, stress kinases. 
 
 
Introduction 
 
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder and the most 
common cause of dementia affecting elderly people. Around thirty-five million people 
are now estimated to be affected by AD worldwide. It is expected that the prevalence of 
AD and dementia will double in the next decades mainly due to extension of life 
expectancy in developed countries and to metabolic risk factors exposure (1). For 
example, common metabolic diseases like obesity and diabetes mellitus have been 
described as AD risk factors (2). Indeed, neuropathological studies have revealed that 
AD brains present several markers of inflammation, insulin resistance and endoplasmic 
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reticulum (ER) stress (3-8). Early onset forms of the disease have familial aggregation 
and are generally caused by rare autosomal dominant mutations in genes codifying for 
proteins involved in Aβ production like the amyloid precursor protein (APP), presenilin-
1 and presenilin-2. Nonetheless, the big majority of AD cases has a late onset 
presentation and is sporadic (9). AD still has no proven preventative intervention, the 
pharmacological treatments are modestly useful only for some symptoms, and, to this 
date, there are no effective disease-modifying therapies. From a cellular point of view, 
AD is associated with aberrant protein processing. Its pathological hallmarks are the 
presence of extracellular aggregates of amyloid-β peptide (Aβ), also known as senile 
plaques, and intracellular clusters of hyperphosphorylated tau protein, commonly called 
neurofibrillary tangles (NFTs) (10,11). Clinically, AD is characterized by a progressive 
loss of cognitive abilities, of which the most affected are memory and learning (12-14). 
 
Historically, classical AD pathophysiological theories were principally focused on the 
amyloid/tau model. Nevertheless, data from last decades has shown that AD is a 
heterogeneuos disorder, in which, of course, amyloid and tau pathology play an 
important role, but within a more intricated and complex mechanism. Hence, recent 
evidence supports the idea of AD as a form of dementia caused by degenerative 
metabolic dyshomeostasis, that typically manifests in the elderly as a result of a 
cumulative, lifelong impact on peripheral tissues and the brain (2,15). One of the widely 
studied metabolic impairments associated with AD is insulin resistance. Thereupon, in 
this report we will focus on how insulin signaling impairment affects AD. Classically, 
since the discovery of insulin in 1922, the brain was considered to be insulin-
insensitive, but evidence has proved the contrary and now it is widely accepted that 
insulin has neuromodulatory actions in the brain. It has been described that the risk of 
AD is at least two-fold higher in patients with type 2 diabetes mellitus (16) and several 
studies have shown that brain insulin resistance has a key role in AD-like alterations 
(17-20). Insulin/IGF-1 signaling is involved in various neuronal functions such as 
synapse transmission and cognition (21) learning and memory (22) as well as 
physiological processes like dendritic sprouting, neuronal stem cell activation, cell 
growth, and both repair and neuroprotection from stressors (23-26). Moreover, insulin 
affects, direct or indirectly, different pathways, enzymes and factors like PI3K/AKT, 
GSK-3β or Aβ oligomers, among others, as we will discuss later on. It is then proposed 
that defective insulin signaling in AD contributes to hyperphosporylation of tau, 
deposition of Aβ, neuroinflammation, synaptic plasticity disruption and consequently, 
	 6	
memory and cognition impairment (27). All the growing evidence indicating that 
impaired insulin signaling is a putative factor governing AD pathology has led 
researchers to consider AD as a brain-specific form of diabetes, often termed as “type 
3 diabetes” (28). In this review we will describe the connection between neuronal 
insulin signaling and the pathogenesis and progression of AD, as well as the new 
therapeutic approaches focused on the insulin signaling pathway that are being 
researched, such as intranasal insulin or insulin sensitizing agents. Our aim is to 
expose in a very clear way the current knowledge regarding the topic without forgetting 
that intense research must follow in the next years in order to answer several open 
questions, and more importantly, in the hope to find an effective treatment for this 
terrible disease. 
 
 
The role of insulin in the brain  
 
As we have mentioned, for a long time it was thought that the brain was insensitive to 
insulin, and not only insulin effects on the brain have been discovered since increasing 
evidence also suggests that insulin is produced locally in the brain and its levels are 
variable coupling with neural demands across the different brain regions (29,30). 
Additionally, pancreatic insulin can actively cross the blood-brain barrier (BBB) and 
circulate in the cerebrospinal fluid (CSF) (31). Brain insulin concentrations can be 10- 
to 100-fold greater than plasma levels, particularly in the hypothalamus, hippocampus, 
cortex, olfactory bulb, substantia nigra and pituitary gland (32,33). Similar to insulin, 
IGF-1 is present in the human brain and is able to cross the BBB (34). 
 
The role of insulin/IGF-1 signaling in the neuroendocrine brain, regulating the 
peripheral metabolism via insulin receptors (IRs) and insulin-like growth factor 
receptors (IGFRs) is well known (35).  However, accumulating evidence indicates that 
IRs and IGFRs are not only present in the neuroendocrine brain but are also widely 
distributed throughout the encephalon. IRs and IGFRs are especially abundant in brain 
regions intrinsically related to memory such as the forebrain, including the 
hippocampus, a fundamental region in the generation of new memories (36-38). The 
discoveries about the IR distribution led researchers to question its role in neuronal 
function.  Consequently, several studies were carried out analyzing this fact and now it 
is quite well established that insulin signaling is crucial for neural development, 
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synaptic plasticity, synaptogenesis, learning and memory in animal models (39-42). 
However, some paradoxical evidence exists contrary to this notion, as is the case of 
one study using NIRKO mice (mice with neuron-specific disruption of the IR gene) 
which showed no spatial memory alterations or even some benefits related to the 
disruption of the insulin signaling pathway in the subjects studied (43).  One possible 
explanation for this fact could be the existence of compensatory mechanisms that 
stimulate the insulin-signaling pathway via other receptors such as the GLP-1 or 
IGF1R. Nevertheless, despite of this counterpoint, the majority of reports have 
concluded that insulin/IGF resistance impairs optimal brain function. To exemplify, 
deficient neuronal insulin receptor signaling causes brain developmental abnormalities 
(44,45), monoamine metabolism impairments and depressive-like behavior (46), 
reduces synaptic density and plasticity (47,48) and increases AD-related tau 
phosphorylation (43). Supporting this trend, in 2012 Nisticò and colleagues showed 
that haploinsufficiency of the B-subunit of the insulin receptor impairs long-term 
potentiation (LTP) and memory acquisition in mice, remarking the key role of insulin 
receptors in memory formation (41). Additionally, intracerebroventricular administration 
of streptozotocin, a toxic compound for the insulin-producing beta cells of the 
pancreas, has been demonstrated to impair brain insulin signaling, leading to both 
reduced short-term object-recognition memory and long-term spatial memory (49). 
Moreover, as we will further develop, exogenous insulin can improve neural 
transmission, brain metabolism and memory in animal models and in humans (26). In 
animal models, insulin increases synaptic density (50), facilitates LTP (51), stimulates 
neurogenesis (52), prolongs cultured neurons survival under physiological (53) or 
stress conditions (54,55) and improves spatial learning and memory (56,57). In 
humans, clinical trials using intranasal insulin report some benefits in individuals with 
mild cognitive impairment (MCI) and AD patients. We will analyze this issue in the 
sections below. 
 
 
The Brain Insulin Signaling Pathway 
 
IR and IGF-1R are tetrameric membrane glycoproteins of the receptor tyrosine (Tyr) 
kinase superfamily composed of two extracellular α subunits (binding region) and two 
transmembrane β subunits (commands the tyrosine kinase activity) (58). Insulin and 
IGF-1 peptides use identical intracellular signaling machinery and can activate both IR 
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and IGF-1R (see figure 1A) but they have higher affinity for their own respective 
receptors (59). Additionally, insulin receptors are able to modulate neurotransmission 
by altering GABAergic and glutamatergic receptor activity. NMDA glutamatergic 
receptors can increase the opening of its associated Ca2+ channels (60) and IR 
activation affects GABA transmission by recruiting functional GABA receptors to the 
postsynaptic site (61).  
 
In order to simplify and clarify the pathway we will focus on the main molecules 
involved in the AD insulin signaling pathophysiology. Thus, the insulin signaling profile 
has two major branches: 1) the phosphatidylinositol 3 kinase (PI3K)/protein kinase B 
(AKT) pathway. 2) the mitogen-activated protein kinase pathway (MAPK)/extracellular 
signal-regulated kinase cascade (62). Ligand binding leads to the autophosphorylation 
of the IR followed by tyrosine phosphorylation of the insulin receptor substrate (IRS) 
protein family (mainly IRS-1 and IRS-2 in the CNS), triggering the activation of the 
downstream pathways mentioned (PI3K and MAPK) (63). PI3K/AKT, for example, 
which seems to be the major insulin-dependent pathway involved in AD cognitive 
decline, targets diverse downstream pathways including mTORC1, GSK3β and the 
FoxO transcription factors family (42). mTORC1-mediated protein synthesis is 
important for synaptic plasticity (64). mTORC1 is also involved  in the regulation of 
neuronal autophagy. Dysregulation of mTORC1-dependent neuronal autophagy ends 
in neuronal cell death and neurodegeneration (65). GSKβ regulates important neuronal 
aspects such as polarity, progenitor cell proliferation and neuroplasticity (66). 
Furthermore, of special relevance for this report is the fact that GSKβ can 
phosphorylate the tau protein, which is well-known for its implications in the 
pathogenesis of AD.  Insulin stimulates GSKβ phosphorylation reducing its enzymatic 
activity. Hence, any situation potentially able to decrease GSKβ activity, such in brain-
specific insulin resistance, increases tau hyperphosphorylation, a hallmark of AD 
(67,43). Moreover, the MAPK cascade plays a main role in cell proliferation, 
differentiation, cytoskeletal reorganization and gene expression contributing to the 
survival of neuronal cells (68). As the reader will notice, IRS is a critical switch in the 
insulin-signaling pathway. Interestingly, the phosphorylation of IRS-1 on multiple serine 
(Ser) residues can inhibit the IRS-1 activity, leading to insulin resistance (69).  
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Insulin-mediated AD pathology 
 
Based on experimental and post-mortem brain studies the brain insulin signal 
transduction system has been proposed to be  involved in the etiopathogenesis of AD. 
Early studies showed a clear reduction of IRs and receptor-kinase activity markers in 
AD brain tissue while posterior investigations have reported increased concentrations 
of both cytosolic IRs and IGF-1Rs compared to plasma membrane levels, suggesting 
that neurons could become resistant to insulin/IGF-1 signaling in the course of AD 
(5,70,71). Furthermore, reduced levels of IRS-1 and IRS-2, key components of the 
signaling, are disease-stage related and strongly correlate with neurofibrillary tangle 
pathology (5). Since insulin and IGF-1 share the same downstream pathway and 
adaptors it is hard to determine the relative contribution of IRs and IGF-1Rs to 
signaling disruption in AD. Various studies have been carried exploring this issue but 
several questions still remain open (43,72). Brain insulin resistance resulting from 
intracerebroventricular injection of streptozotocin has been shown to be mediated by a 
reduced IR gene expression in the hippocampus and the frontoparietal cortex (73), a 
reduced IGF-1R gene expression in the cortex and striatum (74) and an increased 
activation of GSK-3 in the hippocampus (75). Moreover, insulin resistance induced by 
intracerebroventricular injection of streptozotocin in AD transgenic mice exacerbates 
mice neuropathology (76). In addition, an increase in the levels of insulin resistance 
biomarkers have been found in the hippocampi of non-diabetic AD patients, reinforcing 
the connection between insulin signaling alterations and dementia (7,77,78). Summing 
up, evidence demonstrates that AD can be considered a brain-specific form of 
diabetes. AD brains display insulin resistance (see figure 1B). 
 
 
Aβ oligomers neurotoxicity and brain insulin signaling in AD 
 
Even though Aβ oligomers (AβOs) have been known for decades to be a pathological 
hallmark of AD, just recent discoveries have clinically linked these neurotoxins with AD 
insulin resistance. Initially, it was thought that large insoluble Aβ fibrils, deposited as 
amyloid plaques and easily recognized in AD brains, were the cause of neuronal death 
in AD. Subsequently, this hypothesis proved to be not very accurate, due to 
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postmortem analysis of patients with abundant brain amyloid deposits which had 
shown neither cognitive nor intellectual deterioration (79). Evidence has established 
that the best correlate to the extent of dementia is not amyloid burden, but synapse 
loss. Finally, small oligomers have been more recently shown to be implicated in AD 
neuronal disruption. The so called Aβ oligomers (AβOs) are not easily found in 
anatomopathological studies, and are now considered to be responsible of synapse 
failure (79,80). Townsend and colleagues described in 2007 that soluble Aβ peptides 
could bind to neuronal insulin receptors, inhibiting its autophosphorylation (81) (see 
figure 1B).  One year later, another research group showed that the exposure to AβOs 
caused impairment in the neuronal insulin receptor activity and triggered the removal of 
IRs from the dendritic plasma membrane (82). Curiously, these IRs are not degraded 
but accumulated inside the cell body in a non-functional state (83). This redistribution 
mechanism has been proposed to be one of the leading causes of neuronal insulin 
resistance in AD brains and seems to be mediated by NMDA receptors and 
calcium/calmodulin-activated kinase IIα (CamKIIα) (5,7,83). According to these 
evidences, AβOs disrupt IRs homeostasis, impairing the normal insulin signaling 
functioning and thus contributing to AD and dementia. On the other hand, insulin signal 
contributes to the clearance of AβOs, as shown by Zhao and colleagues. Their study 
concluded that insulin receptor dysfunction impairs cellular clearance of neurotoxic 
AβOs (84). As a result, a question comes up: can we neutralize AβOs toxicity by 
stimulating the insulin receptor with its natural ligand, i.e. insulin? Evidence showed 
that insulin pretreatment counteracted oligomer-induced neurotoxicity (81) and 
absence of synapse loss (83). In addition, insulin pretreatment prevented the 
pathogenic binding of AβOs to IR, suggesting that they may bind to the same site, or 
close by (83). Therefore, one of the mechanisms by what insulin improves insulin 
signaling and benefits dementia patients is by preventing AβOs neurotoxicity. 
Theoretically, increased levels of insulin would raise the percentage of insulin-bound 
receptors, hence increasing the potential availability for signaling, obviously in a 
scenario where insulin resistance is not yet established or at least not fully established.  
This is one of the reasons why insulin is thought to be more effective in AD early 
phases than in the late stages of the disease,  as we will discuss further on. As we see, 
different actors are involved in the scenario adding complexity to the equation, such is 
the case of the insulin degrading enzyme (IDE). IDE can degrade Aβ in neuronal and 
microglial cell cultures, eliminating its neurotoxic effects (85-87). IDE expression is in 
turn controlled by insulin levels via the PI3K pathway (88,89), so if the insulin levels 
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drop, there will be less IDE and consequently more Aβ. Moreover, one study showed 
that IDE knockout mice exhibited elevated levels of cerebral Aβ (90). On the contrary, 
overexpression of IDE in the AβPP double transgenic mice reduced brain Aβ levels, 
preventing Aβ plaque formation (88). Another study showed that AD brains had lower 
Aβ degrading activity by IDE compared to controls (91). There are still a lot of open 
questions to answer, for instance, one study found that extreme hyperglycemia per se 
can independently raise Aβ (92). Another example is that chronic hyperinsulinemia can 
down-regulate insulin BBB transport (93) and this obviously would have an impact on 
Aβ. Thus, it is important to have a wide approach and have all these ideas on mind 
while unraveling the process. 
 
Aβ oligomers neurotoxicity is not the only mechanism involved in AD insulin signaling 
impairment. Some reports have shown that abnormal serine phosphorylation of IRS-1 
occurs in the hippocampus and other cortical regions in AD (94). Interestingly, it has 
been described that AβOs increase neuronal IRS-1 phosphorylation at different serine 
residues while decreasing tyrosine residues phosphorylation (6). This is very important 
because IRS phosphorylation at serine or tyrosine residues determines the extension 
of insulin actions. IRS-1 inhibition by P-Ser phosphorylation is mediated by PKR and 
JNK kinases in response to oxidative stress and inflammatory processes (6,95-97). 
Abnormal PKR and JNK activity promotes neuronal degeneration and they are 
overactivated in AD (6,96,97) This IRS-1 phosphorylation pattern was found in post-
mortem AD brains (7). Neuroinflammation is, thus, very likely to play an important role 
in the development of brain insulin resistance in AD (98). In fact, tumor necrosis factor 
α (TNF-α), a main cytokine synthesized and secreted by microglia, the brain resident 
macrophages, activates JNK and PKR stress kinases (99). The circulating levels of 
TNF-α are increased in AD patients and anti-TNF-α therapies are able to improve 
cognition and neuropathology in AD mouse models (96,100-102). Other studies have 
shown that AβOs promote the hyperreactivity of both astrocytes and microglia, as well 
as the stimulation of TNF-α expression and release (103,104). AβOs not only promote 
the expression and release of pro-inflammatory cytokines, but it might also be 
impeding microglial cells from scavenging amyloid deposits through phagocytosis 
(104,105). Is it possible to counteract the neuronal impact of AβOs by stimulating anti-
inflammatory actions or by enhancing amyloid clearance? Several teams are working 
on these questions (106-108). Meanwhile, other approaches  target the TNF-α receptor 
1 (TNFR1) by genetic ablation (96) or by using infliximab, a monoclonal antibody, to 
	 12	
neutralize the soluble TNF-α. Both strategies have been proven to protect neurons 
from AβO-induced IRS-1 inhibition (6) and to block cognitive impairment in mice 
injected with oligomers i.c.v. (96). As we have denoted, evidence shows that the 
development of insulin resistance in AD probably has some mechanisms in common 
with diabetes but it is also important to consider that presumably this is not the only 
mechanism involved, based on the findings of how an increase in cytokine levels may 
impact neuronal function and contribute to AD pathogenesis (98,109). Cytokine 
receptors proximity to synapses may be contributing to insulin signaling defects 
(110,111). On the whole, it seems that pro-inflammatory signaling plays a key role in 
AβO-induced synapse loss and memory impairment in mice (96). Future research will 
disclose more details about the specific mechanisms involved.   
 
Another actor involved seems to be the protein mammalian target of rapamycin 
(mTOR), a well-known downstream signaling effector in neurons and other cell types. 
Although the impact of mTOR in AD is not yet fully understood, we know that mTOR 
kinase activity is crucial for insulin-stimulated protein synthesis and that it also 
mediates synaptic plasticity and memory formation (112,113,114). Regarding AβOs, 
evidence shows that impaired mTOR-dependent autophagy triggered by insulin 
resistance enhances brain Aβ levels (115). There is controversy about how insulin 
signaling affects mTOR and the consequences of mTOR disregulation, because both 
high and low levels might impair neuronal function so the hypothesis is that an 
intermediate optimal range is needed for proper brain homeostasis. Additionally, 
mTOR function is affected by multiple regulators so it is not surprising to find 
controversial results.  
 
Tau phosphorylation and neurofibrillary tangles (NFTs) 
 
As mentioned above, under normal conditions, insulin and IGF-1 activate the PI3K/AKT  
pathway inactivating GSK-3β and resulting in a controlled tau phosphorylation. Thus, 
any reduction in brain insulin signaling will decrease GSK-3β phosphorylation, which in 
turn will increase abnormal tau phosphorylation (84,116). Tau hyperphosphorylation 
promotes the accumulation of neurofibillary tangles (NFTs) in neurons and induces cell 
death (117,118). IGF-1 and IRS-2 gene deletion in knockout mice models leads to 
increased levels of tau phosphorylation (65,119). Furthermore, streptozotocin 
administration also induces tau hyperphosphorylation by inhibiting insulin signaling 
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(49,120). GSK-3β has been most extensively studied as a tau kinase, but it is also 
involved in Aβ production (121). Interestingly, peripheral hiperinsulinemia may result in 
active GSK-3β and high tau protein deposits (122,123). This is likely due to the serine 
phosphorylation of IRS as a result of the negative feedback induced by 
hypersinsulinemia (124). 
 
 
 
 
 
Figure 1. Aberrant brain insulin signaling in Alzheimer’s disease (AD). 
Schematic outline of neuronal insulin signaling in the normal brain (A) and AD brain 
(B). Under physiological conditions, insulin binding to its receptor triggers 
phosphorylation of insulin receptors substrate-1 (IRS-1). This results in phophoinositide 
3-kinase (PI3K) activation and downstream cellular responses that facilitate neuronal 
growth, neuronal survival, synaptic plasticity, learning and memory, etc. Activation of 
the IR can result in both vasodilatation and vasoconstriction and under physiological 
conditions there is a balance of both processes to regulate the immediate metabolic 
requirements of various tissues. In AD, accumulation of amyloid-β oligomers (AβOs) 
leads to increased tumor necrosis factor-alpha (TNF-α) levels and activation of stress 
kinases such as c-Jun N-terminal kinase (JNK) resulting in inhibitory serine 
phosphorylation of IRS-1 (1). Aβ oligomers cause removal of IRs from the cell surface 
mediated by Casein Kinase 2 (CK2) and Ca2+/Calmodulin-Dependent Kinase II 
(CaMKII) and redistribute them to cell bodies (2). Insulin resistance lowers the 
expression of Aβ-degrading insulin degrading enzyme (IDE) (3). Lowered IDE 
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expression further decreases the availability of IDE for Aβ degradation. The reduction 
in brain insulin signaling increases GSK-3β activity (4), which increases abnormal tau 
phosphorylation. Deficient insulin signaling leads to impairment in nerve growth, 
synaptic plasticity, learning and memory, etc. (5). Aberrant phosphorylation of IRS 
causes an imbalance in homeostatic regulation of vascular function (6). This decreased 
production of NO may result in decreased cerebral blood flow and increased pro-
inflammatory cytokines and reactive oxygen species production.  
 
Extracted and modified from: Bedse G, Di Domenico F, Serviddio G and Cassano T (2015) 
Aberrant insulin signaling in Alzheimer’s disease: current knowledge. Front. Neurosci. 9:204. 
doi: 10.3389/fnins.2015.00204. 
 
 
Neuronal metabolic stress, neuroinflammation and impaired insulin signaling in 
AD 
 
We have described the importance of AβOs neurotoxicity in AD neuropathology. 
Recapitulating, AβOs promote neuronal stress by inducing neuroinflammation, with 
consequent abnormal rising in TNF-α levels and ROS which in turn leads to 
overactivation of JNK/PKR stress kinases signaling (6,96,125,126). The activation per 
se is not problematic, in fact, stress kinases activation regulates homeostasis. 
However, their exceeding or lengthened actions provoke cell damage and later 
apoptosis (126-129). Not only JNK and PKR are involved, AD brains have also been 
reported to present abnormal phosphorylation levels of PERK (3,130), p38 MAPK (131) 
and IKK (7). All these stress kinases are thought to be core factors of neuronal 
dysfunction. JNK, PKR and IKK mediate AβO-induced IRS-1 inhibition in hippocampal 
neurons (see figure 2) (6,96). Studies have shown that PKR and JNK blockage 
protects, at least partially, from cognitive impairments in mouse models of AD (96,132). 
 
Thus, neuroinflammation plays a leading role in AD. Human and mice models of AD 
have shown elevated markers of inflammation (98,133,134). There is evidence of 
gliosis and central infiltration of peripheral immune cells in AD mouse models 
(98,107,133,134,136,137). Amyloid aggregates, predominantly oligomers as we have 
mentioned, promote a neuroinflammatory profile that causes synaptic and neuronal 
damage through TNF-α, cytokines and stress signaling (96,134,138-141). Furthermore, 
it is possible that AD could be more susceptible to peripheral inflammation as the BBB 
of AD transgenic mouse models has been described to be more permeable (142).  
Most interestingly, reducing neuroinflammation can counteract memory deficits in AD 
mouse models (101,102,143,144), so that probably future research will reveal new 
therapeutic targets aiming to stop or slow down AD cognitive impairment. Likewise, the 
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insulin signaling pathway is clearly affected by neuroinflammatory processes. AD 
metabolic stress theory is relatively recent compared to the amyloid and 
hyperphosphorylated tau classical theories. Although the specific mechanisms 
responsible for the synaptic defects have not been fully elucidated, little by little our 
understanding of the factors involved as well as their interrelation is growing. In line 
with the metabolic approach, we also know that excessive ROS levels are part of AD 
etiology and AβOs may be the causal agents, via Ca2+-related mitochondrial 
dysfunction that could trigger an aberrant excitatory stimulation of NMDA receptors 
(124,145). This is relevant because oxidative stress and neuronal insulin signaling 
seem to be connected, as studies disclose that insulin blocks AβO-induced oxidative 
stress in the brain (83,146).  
 
 
 
Figure 2. AβOs trigger neuronal metabolic stress in Alzheimer’s disease (AD). 
AβOs instigate an inflammatory response which involves increased TNF-α levels. 
TNF-α promotes the activity of stress kinases like JNK, PKR and IKKα. Stress kinases 
provoke the inhibitory phosphorylation (pSer) of IRS-1, causing defective insulin 
signaling and leading to neuronal dysfunction, synapse deregulation, memory and 
cognitive impairment. 
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Dysfunctional insulin signaling in AD as a target for treatment 
 
As discussed above, defective insulin signaling is intimately associated with AD 
neuropathology and memory impairment. Therapies targeting brain insulin signaling 
are expected to improve AD treatment. Agents like insulin, metformin, GLP-1 agonist, 
PPAR-γ agonists and agmatine are being researched. Evidence shows that insulin 
treatment, both intravenously and intranasally, can modestly improve performance on 
memory tasks in healthy individuals and in patients with AD or mild cognitive 
impairment (MCI) (147-153). Both acute and chronic intranasal insulin treatment (160 
IU/day) enhance memory and mood in healthy adults (154-157) and in patients with 
MCI or in the early stages of AD at various doses (10, 20 and 40 IU) (see figure 3) 
(153).  Systemic administration of insulin is not a good option for treating AD due to the 
risk of developing hypoglycemia and because insulin affects other hormones like 
cortisol, among others. Intranasal delivery is a non-invasive way of bypassing the BBB 
via the nasal epithelia with a small effect on peripheral glucose levels (153). On the 
other hand, gender and the presence of the APOE4 allele modulate the effects of 
insulin (149,153). For example, only APOE4 negative individuals showed improved 
declarative memory after insulin treatment (158). However, we do not know if it 
correlates with an increment in insulin signaling or if it offers protection against 
neuronal damage, in any case, neither theory excludes the other (159). The rise of 
hippocampal insulin and insulin signaling in mice also increases memory. 
Nevertheless, one study showed that mice with type 2 diabetes induced by a high fat 
diet did not present any improvement with insulin therapy (57). This fact supports the 
theory that once insulin resistance has been established, it is probable that insulin 
treatment will not be very benefitial, so it is likely that the biggest benefits from insulin 
treatment come from its application at the initial phases of the disease, as we have 
mentioned before. Recent investigations have pointed out the possibility of insulin 
working through indirect pathways to influence cognition. For instance, Novak and 
colleagues reported that intranasal insulin increases regional cerebral blood flow and 
cognition in type 2 diabetes patients (160). Determining the exact mechanisms through 
which intranasal insulin enhances cognition and whether neuronal insulin signaling is 
required or not, will unlock new specific approaches for treatment without potential 
harmful side effects like raising Aβ or tau. Having on mind that insulin is probably not 
very effective in the late stages of AD, new research has focused in the search of 
antidiabetic drugs that replicate insulin cellular actions independently from insulin 
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receptors activation. Such is the case of peroxisome proliferator-activated receptor γ 
(PPAR-γ) agonists, metformin and GLP-1 agonists.  
 
PPAR-γ agonists are insulin sensitizers with neuroprotective effects. In AD research, 
rosiglitazone and pioglitazone have been shown to improve the microglia ability of 
clearing amyloid deposits. Moreover these molecules can modify gene expression and 
restore both memory and cognition impairment in AD mouse models (107,108,161-
163). Additionally, PPAR-γ stimulation also improves synapse density in cell cultures 
(84) and reduces Aβ levels in AD transgenic mice (164). 
 
Another option tested for AD has been the insulin-sensitizer agent metformin, a widely 
used antidiabetic drug. Metformin was able to reduce AD-related neuropathology in a 
diabetes mice model (165) and to ameliorate insulin resistance in neuronal cell cultures 
(166). Metformin was also found to reduce tau phosphorylation in mice (167). 
Furthermore, metmorfin, as well as physical exercise or thiazolidinediones (TZD) 
improve insulin action via the inhibition of iNOS and mTOR signaling (168,169). 
Nonetheless, as could be guessed, further research about metformin is needed, first, 
because it has not been clinically studied in AD patients, and secondly, because some 
studies have observed that it may increase Aβ production (170,171). At the same time, 
considering the metabolic hypothesis of AD, adopting a healthy lifestyle and strategies 
aimed at lifelong control of blood glucose levels may produce benefits to preserve 
cognition in the elderly and to prevent AD development.  
 
Lately, the National Institute of Health (NIH) has selected intranasal insulin 
administration as one of the two therapeutic strategies receiving substantial funding as 
part of the National Alzheimer’s Plan in the US. This plan is part of an initiative aimed 
at finding a therapeutic treatment to cure AD by 2025. In a double-blind and placebo-
controlled phase II/III clinical trial, subjects will be treated with intranasal insulin or 
placebo for one year; subsequently all subjects will receive the active drug for a 6 
months period. Primary outcome measures include effects on cognitive status, brain 
structure on MRI, changes in cerebrospinal fluid (CSF), AD markers and both 
significance of gender and APOE E4 status for insulin response (172).  More 
extensive, detailed and multi-center clinical trials are still needed to establish the 
beneficial effects of intranasal insulin on cognition and to evaluate its potential side-
effects. 
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Figure 3. Intranasal insulin improves memory in patients with MCI or in the early 
stages of AD (153). Mean memory saving scores (±SEM) in patients with early stage 
Alzheimer’s disease and mild cognitive impairment (MCI) at baseline (day 0) and after 21 
days of treatment with placebo (n=12) and insulin (2 × 20 IU/day; n=13), respectively. 
Insulin-treated patients showed increased memory savings over 21-day period relative to 
placebo. *P value smaller than 0.05  
 
Extracted from: Brain Insulin Signaling and Alzheimer's Disease: Current Evidence and Future 
Directions Helgi B. Schiöth & Suzanne Craft & Samantha J. Brooks & William H. Frey II & 
Christian Benedict Mol Neurobiol (2012) 46:4–10 DOI 10.1007/s12035-011-8229-6.  
 
 
GLP-1 signaling as a promising therapeutic target 
 
Glucagon-like peptide 1 (GLP-1) is an incretin and neuropeptide first known to 
stimulate pancreatic insulin secretion after feeding. GLP-1 receptors are present in 
several brain regions, mostly on large neurons such as pyramidal neurons at the 
hippocampus or cortex and in the Purkinje neurons of the cerebellum (173-175). The 
use of insulin in non-diabetic patients, even intranasal via, is not exempt of risk, not 
only because it can cause hypoglycemia but because it may accelerate insulin 
desensitisation in the brain. Thereupon, new alternatives focused on insulin signaling 
have been proposed, mainly drugs first developed to treat type 2 diabetes, as GLP-1 
analogs (176-178). Up to date, three drugs of this class have been approved for type 2 
diabetes treatment: Exendin-4, lixisenatide and liraglutide (179,180), which in turn are 
under investigation for the treatment of neurodegenerative diseases such as AD. The 
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interesting aspect about these drugs is that they have small side effects, they do not 
directly affect blood sugar levels and they can be administered to non-diabetic patients 
(181,182). Moreover, these drugs can cross the BBB (183), so they are potentially 
effective in treating neurodegenerative disorders of the CNS. GLP-1 analogs can shield 
cultured neurons from stressors, reduce apoptosis and increase cell division (184,185). 
They also protect synapses from injurious effects caused by amyloid deposits in the 
hippocampus (186,187). GLP-1, just like insulin and IGF-1, interferes with PI3K and 
MAPK second messenger signaling pathways (188). Neuroprotective effects have 
been observed in AD animal models after GLP-1 mimetics treatment (189). Exendin-4 
proved itself capable of reducing AD associated biomarkers, as well as endogenous 
levels of beta-amyloid in the mouse brain (190). Likewise, lixisenatide has been shown 
to boost stem cell proliferation and to protect the hippocampus from beta amyloid 
effects regarding memory, learning and synaptic plasticiy in rats (191,192). In addition, 
liraglutide displayed similar effects as lixisenatide, rescued memory formation and  
reduced chronic inflammation response related to AD (193-195).  GLP-1 analogs also 
have been stated to induce neurite outgrowth and to protect against excitotoxic cell 
death in cell cultures (184,185,196). Based on these very promising preclinical studies, 
clinical trials with GLP-1 mimetics in AD patients are being carried. Such is the case of 
liraglutide, which is being tested for efficacy in AD (http://clinicaltrials.gov/ct2/ 
show/NCT01843075). 
 
 
Agmatine 
 
Agmatine is an endogenous aminoguanidine compound derived from L-Arginine which 
has been used in models of several diseases such as stroke, diabetes, spinal cord 
injury and cognitive decline (197). Kang and colleagues showed that agmatine 
administration improved and rescued the reduced expressions of p-IRS1, p-Akt, and p-
GSK-3β in the brain of high-fat diet-fed mice (198,199). It also reduced Aβ burden and 
p-tau accumulation. In addition, agmatine improved impairments in learning and 
memory functions in high-fat diet-fed mice (200). It has been reported as well that 
agmatine can improve insulin sensitivity by activating I2-imidazoline receptors in the 
adrenal glands of diabetic animal models (200). It may also reduce the phosphorylation 
of iNOS and JNK in the brain of type 2 diabetes mice with AD-like alterations 
(201,202). Agmatine improves hippocampus-dependent spatial learning by rescuing  
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blunted insulin signaling in the region (198). However, agmatine could also improve 
hippocampus-dependent spatial learning and memory, not only by rescuing insulin 
signaling but due to its neurotransmitter function (203,204). Further research is needed 
to clarify the direct connection between brain insulin resistance and agmatine. The 
drug has the potential to rescue some AD-like alterations so maybe it could help us 
manage the disease in the future combined with other treatments. 
 
 
Concluding remarks 
 
AD is a dreadful disorder both for the patient and for his family. A family that has to 
witness, impotent, how the disease slowly takes away their beloved one. Until date, no 
therapy has proven to be effective in stopping or reversing the disease. The 21st 
century has turned out to be a scenario where metabolic disorders represent an 
important public health problem, with an impact potentially comparable to that of 
infectious diseases on the 20th century. We can easily see this trend by taking a 
glance at the leading causes of mortality and morbidity worldwide. Cardiovascular 
diseases, cancer, diabetes and obesity, all have a metabolic component. The same 
goes with dementia and AD. In this review, we have centered our attention on 
analyzing the relation between insulin resistance and AD, on how insulin signaling 
disruption promotes AD-like pathology and the mechanisms involved. Insulin 
resistance, AβOs neurotoxicity, neuronal metabolic stress and neuroinflammation all 
have been proven to play a role in AD pathogenesis and to be interconnected. Due to 
its complexity, a lot of questions still remain open, but we hope that sooner than later, 
the answers will come so we can develop better therapies to manage the disease. 
Intranasal insulin, GLP-1 analogs, anti-TNF-α antibodies, gene therapy and agmatine 
have been the most promising treatments up to date, with some of them in the clinical 
trial phase. Other treatments like metformin, PPAR-γ agonists, lipoic acid and 
antioxidant compounds are also being explored but with controversial or doubtful 
results. The future will reveal whether we were able to cure the disease or not, now it is 
our time to make the effort and tilt the balance towards the yes, or maybe we will not 
have to, if the anti-aging progress does the trick first, but that is another topic. 
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